Member Info for shareinterested

why AVCT market value is twice as of ncyt?

I really couldn't figure that out.

anyone with some good explanations, please?

ta

correction on typo: you have two choices

a week ago, my corporation action says to me, i had to choice about their offer. 1 do nothing, I will still hold my shares. 2: accept the offer of 15.5p. I of course did nothing. Expiry date: one day from that day I saw it, probably on 16th?

Today, the corporation action message changed to: compulsory taking over, expiry date 27/Aug, payment will be around two weeks after that!
What the FECK?

we have about $200m in cash, and company value is much lower than sng, considering our cash.
SNG has very good potential in drug application and effectiveness of curing the covid, but they do have the possibility of placing to fund themselves further for trial III

we are trail III on copd.
FDA recommendation on cov19

totally agree bewis.

I feel this will be next sng, I am not saying it will jump on sp 400% a day, I am saying the potential of effectiveness of curing cov19 from copd drug. A potential world changer stock! and much better funded than sng. I was in from the FDA news and topped up twice ever since. Will just hold for a few months to lease out the potential...

i don't understand why people selling now at 85p, as you could sell 20k no problem, but need to go NT for 200 shares.
media coverage all over the weekend and further on.

good luck all holders.

Sng has been great. Been in since 64p, down to 36p. but out half for 170p-220p ish. Still keep rest going, Great drug to help the world in pandemic! more news to come regarding to ce mark, fda and copd.
Check VRP share today. Great news too! FDA news and COPD trial stage III, good value including the $200M capital raise weeks ago....

Good luck all,

DYOR

this indeed is a piece of astonishing news. Malaysia has over 6.6M people of Chinese ethnic and China's affection to all the Southern east Asia from the last twenty years have been HUGE.
This piece of news is absolutely much heavier than last one, and Ali Pay was like paypal, exact powerful, if not more in China and South east Asia.
Will consider to buy a small chunk today myself if the chance is good.

and carry on to a further blue day tomorrow! Looking forward to next RNS
today's whole market was down, look how well iqai has recovered, absolutely brilliant!

Good luck to all holders.

I am happy that i couldn't see the wolf roar, but i can the lovely green colour says Rubbish was filtered. lol
I suggest others do the same.
but, he might talk more when we are north of 6p/7p. Or taking over at 15p?

the herd will return again.

time line: at least ten years to develop a new drug
cost: average $2.6B
sorry for wrong figure from my head.
On average, it takes at least ten years for a new medicine to complete the journey from initial discovery to the marketplace, with clinical trials alone taking six to seven years on average. The average cost to research and develop each successful drug is estimated to be $2.6 billion.

at price of 4.7 and 4.675 each. my first in was at 6.1 and then 5.3.
Hold it till the taking over price was revealed, was hoping for 10M deal.
in the USA, finding a new drug and develop it takes about 25 years and costing over 100M $ each drug on average.
Our software? saves them time and MONEY!

lovely jubbly

Don't understand why that guy was here half of a whole day, talking rubbish with no ground, had to filter him...
Today was a brilliant progressing day for IQAI and shall progress even more tomorrow with a potential multi-million pounds deal with an international sound name within the field. Lovely!

fantastic

Not to see the herd on ncyt, sng, redx and indv, didn't come to here to have a share of the possible sweet cake.

yesterday's result was improved.
Today's test performance? wow, unbelievable! this made me thinking of ncyt and sng , four month ago and two weeks ago, respectively

can't agree with you about 30's more.

I guess a sp of 33-35 should be for certain for today.

esp. when there are three groups of bidders. 40p is mentioned, it meant 40p.
And, shorters need to be out before then...so, share price should be going up!

David Zruia, Chief Executive Officer of Plus500, commented on his appointment and on the results:

"Having been part of the Plus500 team for almost 10 years, I am honoured to be given the opportunity to become CEO of the Company. It has been exciting to lead the business on an interim basis over the last few months and I believe that Plus500 is in an extremely strong position, both operationally and financially, to deliver future growth for our shareholders.

"This position is highlighted by our exceptionally strong performance during the first half of 2020. The significant number of New Customers on-boarded is a strong signal of the sophistication and accessibility of our proprietary technology platform. This performance is also a testament to our people, who have been fully committed to ensuring that we have offered our customers a consistent, seamless, high quality service in extremely challenging, and unprecedented, circumstances.

"Given our performance in the first half, we remain very confident about the prospects for the Company."

Half Year Trading Update

Further to the Company's recent trading updates, issued on 28 April 2020 and 8 June 2020, market volatility remained heightened throughout the second quarter. This drove a consistently high level of customer trading activity which, together with the onboarding of a significant number of New Customers1 at an attractive cost, ensured a record number of Active Customers2 trading on the Plus500 platform during H1 2020. 198,176 New Customers were onboarded during H1 2020 (H1 2019: 47,540), including 115,225 New Customers in Q2 2020 (Q2 2019: 26,234).

As a result, total revenue for H1 2020 was circa $564.2m3 (H1 2019: $148.0m), including circa $247.6m3 in Q2 2020 (Q2 2019: $94.1m), demonstrating the strength, scalability and differentiation of the Group's business model. The Company achieved a record level of half yearly Customer Income4, of approximately $556.9m (H1 2019: $175.0m), including circa $323.4m in Q2 2020 (Q2 2019: $93.0m). Furthermore, the period-end position of Customer Trading Performance5 reverted to insignificant historical levels, with revenues from Customer Trading Performance representing approximately 1% of the total revenues in the period.

The unprecedented market environment during the period, the consistently high level of quality and performance of Plus500's market-leading proprietary technology platform and the continued dedication and hard work of our employees in extremely challenging circumstances ensured that customer retention remained strong.

The Company's financial position remains robust, driven by the strong EBITDA margin achieved during the period and continued high cash generation, as well as the minimal capital expenditure requirements and the low capital intensity of the business.